Showing 1 - 6 results of 6 for search 'Quanren Wang', query time: 0.03s Refine Results
  1. 1
    bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy

    bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination... by Gehan Xu, Liang Cui, Jin Li, Quanren Wang, Pansong Li, Xuefeng Xia, Xin Yi, Quanlin Guan, Jianming Xu

    Published 2022-10-01
    Get full text
    Article
  2. 2
    Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

    Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket st... by Qi Zhou, Yu Zhang, Jin Peng, Xiaohua Wu, Quanren Wang, Yunong Gao, Ge Lou, Huirong Shi, Rong Sun, Jianqing Zhu, Lingfang Xia, Mei Pan, Wenjing Hu, Xianfeng Zhou

    Published 2022-01-01
    Get full text
    Article
  3. 3
    Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study

    Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study by Quanren Wang, Qing Zou, Chunxia Chen, Hong Luo, Yuan-Yuan Qu, Zhongquan Sun, Weiqing Han, Nianzeng Xing, Xuepei Zhang, Chaohong He, Xiao-Jie Bian, Jinling Cai, Ding-Wei Ye

    Published 2022-05-01
    Get full text
    Article
  4. 4
    A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis

    A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation an... by Yaxin Liu, Wei Wang, Rutie Yin, Youzhong Zhang, Yu Zhang, Keqiang Zhang, Hongming Pan, Ke Wang, Ge Lou, Guiling Li, Ruyan Zhang, Kun Li, Jing Rao, Ben Zhang, Yuting Wang, Quanren Wang, Yunong Gao, Huiping Li

    Published 2023-09-01
    Get full text
    Article
  5. 5
    Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study

    Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study by Wencheng Zhang, Cihui Yan, Tian Zhang, Xi Chen, Jie Dong, Jingjing Zhao, Dong Han, Jun Wang, Gang Zhao, Fuliang Cao, Dejun Zhou, Hongjing Jiang, Peng Tang, Lujun Zhao, Zhiyong Yuan, Quanren Wang, Ping Wang, Qingsong Pang

    Published 2021-01-01
    Get full text
    Article
  6. 6
    Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

    Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial by Shengxiang Ren, MD, Jianxing He, MD, Yong Fang, MD, Gongyan Chen, MD, Zhiyong Ma, MB, Jianhua Chen, MM, Renhua Guo, MD, Xiaoyan Lin, MD, Yu Yao, MD, Gang Wu, MD, Quanren Wang, PhD, Caicun Zhou, MD

    Published 2022-05-01
    Get full text
    Article

Search Tools: